- Under FDCA Section 801, which of the following products is automatically deemed adulterated or misbranded and may be refused entry into the United States?
Answer: Any drug, device, or food appearing to violate FDCA standards.
FDCA Section 801 authorizes FDA to refuse admission to any drug that appears to violate the FDCA, including products without U.S. approval, products from non-GMP facilities, and mislabeled products. B correctly describes this broad authority. A is incorrect because the refusal authority extends beyond controlled substances to all FDCA-regulated products. C is incorrect because the refusal authority does not depend on trade agreement status. D is incorrect because while import alerts expedite refusal for known problematic sources, Section 801 authority is not limited to import alert listed products.
- Under what circumstances may the FDA authorize importation of a drug product that is not FDA-approved, under its 'foreign supply' or 'personal use' import authority?
Answer: For personal use when no FDA-approved alternative is available and treatment began abroad.
FDA's enforcement discretion for personal importation of unapproved drugs is based on a set of informal criteria: personal use, limited quantity, no unreasonable risk, continuation of foreign treatment, and not substituting for available domestic options. D correctly identifies these criteria. A is incorrect because a U.S. prescription alone does not satisfy FDA personal importation criteria. B is incorrect because foreign government certification is not an FDA personal importation standard. C is incorrect because financial hardship is not one of the FDA's personal importation discretion criteria.
- Which of the following activities by a U.S. pharmacist is clearly prohibited under federal importation rules?
Answer: Importing prescription drugs from foreign distributors for dispensing without FDA approval.
A pharmacist who purchases drug products directly from a foreign distributor outside FDA-approved importation channels and dispenses them to patients is engaging in illegal drug importation and distribution. C correctly identifies this prohibited activity. A is incorrect because counseling patients about risks is a permitted and encouraged pharmacist activity. B is incorrect because recommending domestic alternatives is within the pharmacist's scope. D is incorrect because accurately informing patients about FDA enforcement discretion is educational, not prohibited.
- Under the FDCA, what is meant by 'reconditioning' in the context of a refused importation?
Answer: Reconditioning means modifying the product to meet FDCA standards under FDA oversight.
Reconditioning is a formal FDCA process by which a refused imported product may be corrected under FDA supervision -- for example, by relabeling a mislabeled product or otherwise bringing it into compliance with FDCA requirements -- so that it can then be admitted to the U.S. market. A correctly describes this process. B is incorrect because reconditioning involves correcting the specific imported product under FDA supervision, not repurchasing from a domestic source. C is incorrect because reconditioning occurs in the United States; returning the product to its country of origin is a separate option known as exportation or re-exportation. D is incorrect because donating the product to a charitable organization is not the definition of reconditioning under the FDCA importation framework.
- The FDA Modernization Act of 1997 included provisions related to reimportation of U.S.-manufactured drugs. Which of the following best describes the reimportation framework?
Answer: The 1997 Act allowed conditional reimportation of drugs from Canada, pending HHS Secretary's safety certification.
The FDA Modernization Act created a conditional reimportation framework requiring HHS Secretary certification of safety -- a certification no Secretary has made, leaving the provision unimplemented. C correctly describes this framework and its non-implementation. A is incorrect because the Act did not authorize unrestricted reimportation. B is incorrect because the provision was not limited to veterinary use. D is incorrect because the Act did not create a permanent prohibition; it created a conditional authorization.
- Under the FDCA, a manufacturer whose drug products are imported from abroad must meet which of the following requirements regarding GMP compliance?
Answer: Foreign manufacturers must comply with U.S. GMP standards, and FDA can inspect and refuse products not meeting these standards.
Foreign manufacturers supplying the U.S. market must meet the same GMP standards as domestic manufacturers. The FDA has authority to inspect foreign facilities and may refuse admission of products from non-compliant facilities. A correctly identifies this standard. B is incorrect because ISO certification does not satisfy FDA GMP requirements. C is incorrect because products entering the U.S. must meet U.S. standards regardless of where they were manufactured. D is incorrect because while FDA jurisdiction is limited outside U.S. borders, products offered for import that were manufactured in non-GMP conditions may be refused admission.
- A state enacts a law authorizing pharmacies in that state to import lower-cost drugs from Canada to reduce prescription drug prices for residents. Under federal law, which of the following applies?
Answer: State laws cannot authorize activities prohibited by federal law; federal FDCA importation requirements preempt state importation authorization; pharmacies acting under the state law may still face federal liability under the FDCA.
Under the Supremacy Clause, federal law preempts conflicting state law. A state law purporting to authorize drug importation prohibited by the FDCA does not shield pharmacies from federal liability. B correctly identifies the federal preemption analysis. A is incorrect because state police powers over pharmacy practice do not override federal importation law. C is incorrect because state police powers are limited by federal supremacy. D is incorrect because the FDA has jurisdiction over imports regardless of bilateral relationships with foreign countries.
- A shipment of foreign-manufactured drug products arrives at a U.S. port of entry and the FDA determines upon examination that the products appear to be misbranded. Which of the following describes the FDA's options?
Answer: The FDA may refuse admission and allow the importer to export or rectify the misbranding.
When FDA refuses admission to imported products determined to be misbranded, the importer typically has an opportunity to either export the products or bring them into compliance within a specified timeframe before the FDA proceeds with destruction. B correctly identifies these procedural options. A is incorrect because FDA may refuse admission; it is not limited to issuing warning letters. C is incorrect because FDA is not required to allow the products to enter the country; refusal of admission is an available and standard FDA option. D is incorrect because the importer is given an opportunity to respond, export, or recondition the product before destruction; immediate seizure without opportunity to respond is not the standard importation refusal procedure.
- A pharmacist working at a U.S.-based specialty pharmacy receives a request to source a specialty biologic from a supplier outside the authorized U.S. distribution channel, even though the drug is FDA-approved domestically. Which of the following best analyzes the compliance concern?
Answer: Sourcing outside authorized channels risks violating FDCA importation laws and DSCSA documentation requirements.
Sourcing an FDA-approved drug outside authorized U.S. distribution channels creates multiple compliance risks: FDCA importation violations, DSCSA chain-of-custody failures, and product integrity concerns. FDA approval covers the product through authorized channels, not through parallel imports. B correctly identifies these risks. A is incorrect because domestic FDA approval does not authorize parallel importation outside authorized channels. C is incorrect because Import Alert status is one of many DSCSA and FDCA compliance considerations. D is incorrect because storage quality is only one of multiple compliance dimensions; importation law and DSCSA apply independently.
- A U.S. hospital wants to use a drug approved in the European Union for a condition in which it believes the European drug performs better than the FDA-approved alternative. Under federal law, what is required?
Answer: FDA authorization via IND or expanded access is required to use an EU-approved drug not approved by the FDA.
Using an FDA-unapproved drug in a U.S. hospital requires either an IND or individual patient expanded access authorization. Clinical belief in superiority does not authorize importation and use. C correctly identifies the required pathways. A is incorrect because a quality agreement with a manufacturer does not satisfy FDCA importation law. B is incorrect because physician prescription does not authorize use of an unapproved imported drug outside an approved IND or expanded access framework. D is incorrect because hospitals are not exempt from FDCA requirements.
- A Section 503B outsourcing facility wants to import a bulk active pharmaceutical ingredient (API) from a foreign manufacturer for use in compounding. Under FDA regulations, what must the foreign manufacturer have in order for the API to be lawfully imported?
Answer: The foreign manufacturer must be registered with the FDA as a drug establishment for the API to be imported lawfully.
Foreign API manufacturers must be FDA-registered, and their APIs must meet applicable standards. The 503B facility must obtain documentation of identity, purity, and quality. C correctly identifies these requirements. A is incorrect because home country licensure alone does not satisfy FDA importation requirements. B is incorrect because FDA registration of the facility is required in addition to the CoA. D is incorrect because APIs used in compounding are regulated under the FDCA and subject to FDA oversight.
- A patient purchases a drug from an online Canadian pharmacy and has it shipped to the United States. The drug is FDA-approved in the U.S. but the imported product comes from Canadian-labeled inventory. Which of the following best analyzes the compliance concern?
Answer: Importing Canadian-labeled drugs into the U.S. is illegal, despite FDA approval of the molecule.
U.S. approval of a drug applies to specific products manufactured and labeled to U.S. standards. A Canadian-labeled product, even containing the same active ingredient, is not an FDA-approved U.S. product. Its importation is technically illegal regardless of the domestic approval status of the active ingredient. B correctly identifies this analysis. A is incorrect because domestic approval applies to the U.S.-labeled product, not to foreign-labeled versions. C is incorrect because Canadian pharmacy licensure does not resolve U.S. importation law. D is incorrect because molecule equivalence does not satisfy the FDA approval framework for specific drug products.
- What is the FDA's enforcement discretion policy regarding personal importation of prescription drugs from foreign countries?
Answer: The FDA may allow personal importation of small drug quantities for personal use under enforcement discretion, not legal authorization.
The FDA's enforcement discretion does not constitute legal authorization; it is a policy of generally not prosecuting small-quantity personal use importation under specific conditions. A correctly identifies the discretion-versus-authorization distinction. B is incorrect because no formal FDA authorization of 90-day personal importation from Canada exists; this has been proposed but not enacted. C is incorrect because the FDCA does not exempt personal use from its importation provisions. D is incorrect because customs duties are a separate matter and paying them does not resolve the FDCA importation prohibition.
- A U.S. nonprofit organization wants to donate foreign-manufactured pharmaceutical products to a disaster relief effort in the United States. The products are not FDA-approved. Which of the following best applies?
Answer: Unapproved foreign drugs require FDA authorization before distribution, even for charitable purposes.
The FDCA applies to drug distribution regardless of whether it is commercial or charitable. Unapproved foreign drugs may not be distributed in the United States even for disaster relief without FDA authorization. A correctly identifies this obligation. B is incorrect because nonprofit or non-commercial status does not exempt drug distribution from FDCA requirements. C is incorrect because disaster relief purposes, while compelling, do not automatically override FDCA requirements. D is incorrect because nonprofit status does not constitute FDA approval.
- Under the FDCA, what is the general rule regarding the importation of prescription drug products into the United States?
Answer: Importation of unapproved prescription drugs is generally prohibited, even if approved in other countries, under the FDCA.
The FDCA generally prohibits importing prescription drug products not approved by the FDA for the U.S. market. This applies to both commercial and personal use importation. B correctly states this general prohibition. A is incorrect because equivalence of foreign standards does not override U.S. import approval requirements. C is incorrect because Canadian drug approval does not substitute for U.S. FDA approval; importation from Canada for individuals is technically prohibited under federal law. D is incorrect because a valid U.S. prescription addresses the prescribing authority but does not resolve the importation prohibition.
- A pharmacist is asked by a patient whether she can legally purchase prescription medications from an online pharmacy based in another country and have them shipped to her U.S. address. Which of the following is the most accurate response?
Answer: No, purchasing prescription drugs from foreign online pharmacies for U.S. delivery is illegal under federal law.
Purchasing from a foreign online pharmacy and importing to the U.S. is technically illegal under the FDCA. The FDA's enforcement discretion is not a legal authorization. Patients should understand the legal risk, safety concerns about product authenticity, and quality issues. D correctly describes this analysis. A is incorrect because foreign pharmacy licensure does not satisfy U.S. importation law. B is incorrect because a valid U.S. prescription addresses prescribing authority but not the import prohibition. C is incorrect because no FDA-authorized quantity exemption exists for this type of purchase.
- Under the FDCA, what is an Import Alert, and what effect does it have on importation?
Answer: An Import Alert allows FDA to detain products at the border without physical examination.
An Import Alert is an FDA notice identifying known or suspected violators, allowing products from those sources to be detained without physical examination at the port of entry. B correctly describes the nature and effect of Import Alerts. A is incorrect because Import Alerts do not create fee obligations; they create detention authority. C is incorrect because Import Alerts are FDA documents, not foreign government notifications. D is incorrect because detained products are held pending FDA review and may be exported, reconditioned, or destroyed, but not automatically destroyed.
- A drug is available in the United States only through a REMS program requiring patient enrollment. A patient wants to import the same drug from a foreign country where it is available without restrictions. Which of the following best applies?
Answer: Importing a REMS-restricted drug bypasses safety measures and is prohibited under the FDCA.
Importing a foreign version of a REMS-restricted drug is doubly problematic: it violates FDCA importation law and bypasses REMS safety requirements specifically created to manage serious drug risks. D correctly identifies both dimensions. A is incorrect because FDCA importation law applies regardless of REMS status. B is incorrect because REMS safety obligations are compelling reasons to apply additional scrutiny to such importation. C is incorrect because a foreign physician's prescription does not resolve U.S. importation law or REMS requirements.
- Which of the following best describes the FDA's authority to detain imported drug products at U.S. ports of entry?
Answer: The FDA can detain imported drugs if they appear to violate the Food, Drug, and Cosmetic Act.
Under FDCA Section 801, FDA may detain and refuse admission to imported drugs that appear to violate the FDCA. Detained products are held at the importer's expense pending admissibility determination. D correctly identifies this authority. A is incorrect because FDA's detention authority is not conditioned on an importer's documentation failure within a 48-hour window. B is incorrect because FDA exercises independent detention authority without requiring Customs Service direction. C is incorrect because FDA's detention authority extends to all imported drug products that appear to violate the FDCA, not only controlled substances.
- Under FDA import regulations, which of the following entities must be registered with the FDA before importing or offering drugs for importation into the United States?
Answer: Foreign manufacturers must register with the FDA before importing drugs.
FDCA Section 510 requires foreign drug establishment registration for any manufacturer, repacker, or relabeler supplying drugs to the U.S. market. Unregistered facilities' products may be refused at the border. D correctly identifies this requirement. A is incorrect because the foreign manufacturer must also register. B is incorrect because both parties have registration obligations. C is incorrect because registration is mandatory, not voluntary, for foreign establishments supplying the U.S.
